Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Equity Ratio (2016 - 2020)

Historic Equity Ratio for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to 0.96.

  • Monopar Therapeutics' Equity Ratio rose 641.53% to 0.96 in Q3 2020 from the same period last year, while for Sep 2020 it was 0.96, marking a year-over-year increase of 641.53%. This contributed to the annual value of 0.95 for FY2019, which is 3.83% up from last year.
  • Latest data reveals that Monopar Therapeutics reported Equity Ratio of 0.96 as of Q3 2020, which was up 641.53% from 0.95 recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Equity Ratio ranged from a high of 0.98 in Q4 2016 and a low of 0.91 during Q3 2019
  • Over the past 5 years, Monopar Therapeutics' median Equity Ratio value was 0.96 (recorded in 2018), while the average stood at 0.95.
  • Per our database at Business Quant, Monopar Therapeutics' Equity Ratio crashed by 614.69% in 2019 and then soared by 641.53% in 2020.
  • Quarter analysis of 5 years shows Monopar Therapeutics' Equity Ratio stood at 0.98 in 2016, then fell by 0.93% to 0.97 in 2017, then dropped by 2.39% to 0.95 in 2018, then increased by 0.04% to 0.95 in 2019, then increased by 1.87% to 0.96 in 2020.
  • Its last three reported values are 0.96 in Q3 2020, 0.95 for Q2 2020, and 0.97 during Q1 2020.